ASP7517

· Astellas Pharma Global Development, Inc.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for ASP7517, covering 2024-06-25 to 2025-08-08. Get the full timeline:

Most recent: Clinical Trial Update: Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen [Phase 1, Phase 2]

See pricing